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Abstract
Xenotropic murine leukemia virus (MLV)-related retrovirus (XMRV) was reported to be associated with prostate cancer by
Urisman, et al. in 2006 and chronic fatigue syndrome (CFS) by Lombardi, et al. in 2009. To investigate this association, we
independently evaluated plasma samples from 4 patients with CFS reported by Lombardi, et al. to have XMRV infection and
from 5 healthy controls reported to be XMRV uninfected. We also analyzed viral sequences obtained from supernatants of
cell cultures found to contain XMRV after coculture with 9 clinical samples from 8 patients. A qPCR assay capable of
distinguishing XMRV from endogenous MLVs showed that the viral sequences detected in the CFS patient plasma behaved
like endogenous MLVs and not XMRV. Single-genome sequences (N = 89) from CFS patient plasma were indistinguishable
from endogenous MLVs found in the mouse genome that are distinct from XMRV. By contrast, XMRV sequences were
detected by qPCR in 2 of the 5 plasma samples from healthy controls (sequencing of the qPCR product confirmed XMRV not
MLV). Single-genome sequences (N = 234) from the 9 culture supernatants reportedly positive for XMRV were
indistinguishable from XMRV sequences obtained from 22Rv1 and XMRV-contaminated 293T cell-lines. These results
indicate that MLV DNA detected in the plasma samples from CFS patients evaluated in this study was from contaminating
mouse genomic DNA and that XMRV detected in plasma samples from healthy controls and in cultures of patient samples
was due to cross-contamination with XMRV (virus or nucleic acid).
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Introduction
In 2006, a novel infectious agent, xenotropic MLV-related
virus (XMRV), was identified by hybridization to an oligonucle-
otide chip (‘‘virochip’’) and reported to be associated with
prostate cancer [1]. Subsequently, XMRV infection was reported
to be associated with chronic fatigue syndrome (CFS) by
Lombardi, et al. who detected XMRV, using PCR, in 67% of
samples from CFS patients compared to 3.7% of samples from
healthy controls [2]. Such high frequencies of XMRV infection
prompted concerns about widespread XMRV infection and
stimulated research to determine the prevalence of XMRV
infection worldwide. These efforts failed to detect XMRV in
patients with either prostate cancer or CFS, even among a subset
of patients from the original Lombardi, et al. study [3,4] [5–7]
[8,9] [10,11]. These findings suggested that XMRV detection
was the result of laboratory contamination [3,12,13,14,15,16],
which is possible whenever sensitive amplification methods are
employed, such as PCR or viral replication in cell culture. False
positive detection of XMRV in patient samples could arise from
PCR amplification of contaminating XMRV nucleic acids or
from amplification of closely related endogenous retroviruses in
the mouse genome that are misidentified as XMRV. With regard
to the latter possibility, several recent studies have shown frequent
contamination of reagents and samples with mouse DNA
[3,14,17]. In addition, strong evidence that XMRV detection
was the result of laboratory contamination came from a recent
report that XMRV originated as a recombinant virus between
two endogenous MLV proviruses (PreXMRV-1 and PreXMRV-
2) between 1993 and 1996 during passage of a human prostate
cancer xenograft in nude mice [18]. Cells from the passaged
xenograft gave rise to the 22Rv1 cell line, which produces large
amounts of infectious XMRV and has been distributed to
laboratories worldwide [19]. The recombination event that gave
rise to XMRV required multiple crossovers, and it is extremely
unlikely that this complex event could have occurred more than
once. Consequently, any virus whose sequence is closely related
to this exact recombinant virus (XMRV) must have arisen from
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laboratory contamination by XMRV or its descendants. Indeed,
since the generation and distribution of the 22Rv1 cell line,
sublines of several other human cell lines, including Jurkat, 293T,
and LNCap, have been reported to be contaminated with
XMRV or similar viruses in laboratories using the 22Rv1 cell line
[12]. Other cell lines, also derived from cancers passaged in nude
mice, have been shown to be infected with viruses derived from a
variety of endogenous MLVs; however, these viruses are distinct
from XMRV [15,20,21].
To investigate further the possibility that XMRV or MLV
detection in patient samples was the result of laboratory contami-
nation by XMRV or mouse DNA, we performed qPCR and single-
genome sequencing analysis on plasma samples from CFS patients
who were reportedly infected with XMRV [2] and from healthy,
XMRV uninfected controls. We also performed single-genome
sequencing on supernatants from cultures containing XMRV
reportedly isolated from patient samples. Our analyses reveal strong
evidence for three different types of laboratory contamination giving
rise to false positive detection of XMRV in human samples: mouse
genomic DNA contamination of plasma samples from CFS patients;
XMRV nucleic acid contamination of plasma samples from healthy
controls; and contamination with infectious XMRV in virus isolation
cultures. These results indicate that detection of XMRV infection in
the original study by Lombardi, et al. likely arose from laboratory
contamination and cast serious doubt on claims of human infection
by XMRV and other MLVs.
Methods
Patient Plasma Samples
Plasma samples from 4 patients with chronic fatigue syndrome
(CFS) reported to be XMRV-infected by PCR and virus isolation,
performed at the Whittemore-Peterson Institute (WPI) and the
Leukocyte Biology Section (LBS), NCI-Frederick, respectively, and
from 5 XMRV-uninfected, healthy controls were obtained from F.
Ruscetti, NCI-Frederick with permission from J. Mikovits, WPI
(Table 1). All donors signed informed consent forms and the study
was approved by the Institutional Review Board at the WPI
(Approval ID# IRB00000215). Blood samples were drawn into
EDTA-containing tubes by Phlebotomy Services International at
the donors homes on January 21, 2010 and shipped overnight to
LBS. The blood was centrifuged in a BL2* laboratory used for tissue
culture in the LBS, the plasma was removed, aliquoted, and frozen
at 280. The specimens were not reopened prior to testing in the
HIV Drug Resistance Program (DRP). Samples were blinded with
respect to their putative XMRV status by WPI and LBS and were
provided to the DRP in June 2010 for testing by our XMRV single
copy assay (X-SCA) and our XMRV single-genome sequencing
assay (X-SGS) described below. We assigned the 9 blinded plasma
samples identification codes X1–X9. After completion of testing,
samples were unblinded to compare our results with those obtained
by WPI and reported by Lombardi, et al. (Table 1).
Supernatants of Virus Cultures Positive for XMRV
Isolation from Patient Samples
LNCaP cells were co-cultured by LBS with plasma, PBMCs or
tissues (collected from bone marrow biopsies) from 9 clinical
specimens collected from 8 patients with putative XMRV
infection. Virus-positive supernatants were subsequently used
to infect human foreskin fibroblasts (HFFs). The same samples
were opened multiple times for subculture experiments. Exper-
imental cultures were kept in separate incubators from positive
control cultures but were used in the same biological safety
cabinets at different times. Samples of the HFF supernatants
were provided to the DRP in February 2011 and we assigned
them identifying codes DRP ID 1–9 (Table 2). To evaluate viral
sequences in these culture supernatants we extracted viral RNA,
synthesized cDNA, diluted cDNAs ,1011 -fold and performed
X-SGS for gag and env as described below. The description of the
patients’ clinical symptoms, sample type used for virus isolation,
and cell passaging details are shown in Table 2. An additional
plasma sample was collected on March 11, 2010 from one of the
8 patients who had virus isolation performed. This plasma
sample was among the 9 plasma samples described above that
were tested by X-SCA (plasma identifier X5; culture supernatant
identifier DRP PID 5). Single-genome sequences obtained from
this plasma sample (X5) and the virus culture supernatant (DRP
PID 5) were compared.
Cell lines
DNA and supernatants from 22Rv1 cells and the mammary
carcinoma TA3.Cyc-T1 cell line derived from strain A mice,
obtained from V. KewalRamani, NCI, were analyzed by X-SCA
and X-SGS. Results from these cell lines were used as controls for
sequences obtained from patient plasma samples. A subline of
Table 1. Independent evaluation of plasma samples from patients with previously reported XMRV status.
DRP identifier (PID) CFS status XMRV status
X-SCA result
(copies/ml plasma)b X-SGS result mouse COX2 mouse IAP
X1 negative negative negative (,56) negative negative negative
X2a CFS positive mouse (15113) positive positive positive
X3a CFS positive mouse (4730) positive positive positive
X4 negative negative XMRV (177) negative negative negative
X5a CFS positive mouse (471) positive positive positive
X6a negative negative negative (,6) negative negative negative
X7 negative negative XMRV (6423) negative negative negative
X8a CFS positive mouse (2689) positive positive positive
X9 negative negative negative (,9) NTc NT NT
aAs reported in Lombardi, et al [2].
bAs compared to an RNA standard (Figure 1).
cNot tested.
doi:10.1371/journal.pone.0030889.t001
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293T cells was obtained from the LBS for use as an uninfected
control, but was determined by Western blot to be infected with
MLV or XMRV, was confirmed to be XMRV by sequence
analysis, and is referred to as 293T-XMRV. Culture supernatant
and DNA from these cells were subjected to X-SGS for
comparison to virus reported to be isolated from patient plasma
and tissues. We handled all cell culture supernatants in an area
designated for cell culture and not in clean areas designated for
processing of patient samples.
Nucleic Assay Detection with X-SCA
The X-SCA assay [22] is similar to the HIV single-copy assay
(SCA) [23], and can be used to quantify XMRV nucleic acid in
blood and blood products. In brief, virus from patient plasma is
collected by centrifugation after addition of the Rous sarcoma virus
vector RCAS, an internal virion control for recovery [21]. cDNA
was prepared from RNA in the pellet using random DNA hexamers
as primers and subjected to PCR amplification using primers that are
well conserved among XMRV and endogenous MLVs. Conse-
quently, efficient amplification is achieved from both templates, and
the assay can be used to detect either XMRV or MLV sequences in
patient samples. The Taqman probe used for detection of amplified
products was designed to span the signature 9–24 nt deletion in the
XMRV gag leader absent from all endogenous MLV sequences (with
the exception of PreXMRV-2) [18]. This probe design results in a
lower plateau level of fluorescence from sequences amplified from
MLV than from XMRV (Figure 1a), likely due to inefficient binding
and degradation of the probe during amplification of MLV
templates (Figure 1a). The different fluorescence profiles produced
by XMRV and MLV sequences permits their identification and
differentiation [22].
XMRV single-genome sequencing (X-SGS)
The HIV single-genome sequencing assay (SGS) [22] was
modified for amplification and sequencing of single sequences
derived from XMRV and MLV templates (X-SGS). RNA from
virions pelleted from cell culture supernatant was used to synthesize
cDNA using an oligo-dT primer with reaction conditions described
in Supporting Information (Appendix S1). The cDNA was diluted
to ,1 copy per well and amplified using primers targeting XMRV
and MLV sequences listed in Supporting Information (Appendix
S2). cDNA synthesis and PCR reaction components and conditions
were as reported previously [24]. Primers used to sequence single-
genome amplicons are listed in Supporting Information (Appendix
S2). The X-SGS gag protocol generates a 1.4 kb gag sequence and
the X-SGS env protocol generates a 2.1 kb env sequence, which
includes several of the distinctive recombination junctions described
by Paprotka et al. in their paper on the origin of XMRV that
demonstrated that XMRV is a laboratory artifact that arose by
recombination between two MLVs called PreXMRV-1 and
PreXMRV-2 [18]. The total product of each SGS PCR positive
reaction was sequenced. Contigs were generated and sequences
aligned using ClustalW (http://www.genome.jp/tools/clustalw)
and MEGA5 (http://www.megasoftware.net). Alignment trees
were constructed using a neighbor-Joining method in MEGA5.
Detection of mouse mitochondrial DNA and mouse
genomic DNA
We applied two previously developed assays to detect mouse
DNA. The first was adapted from methods developed by W.
Switzer, Centers for Disease Control and Prevention, Atlanta, GA,
to measure the level of mouse mitochondrial DNA by detecting
the cytochrome C oxidase subunit 2 (COX2) gene [25] (Appendix
S3), and the second was adapted from O. Cingo¨z, Tufts
University, Boston, MA, to detect intracisternal A particle (IAP)
sequences [14]. Genomic DNA extracted from as few as 0.0034
cells from the mouse cell line, TA3.Cyc1, could be detected using
the IAP primer set shown in Supporting Information (Appendix
S4). Primer sequences and reaction conditions are described in
Supporting Information (Appendix S3, S4).
Results
MLV-related sequences in plasma samples
X-SCA was performed on 9 plasma samples collected from
donors, 5 of whom were reported in the 2009 Lombardi, et al.
study [2]. Four of the 9 were CFS patients previously reported to
be XMRV positive and 5 were healthy controls reported to
XMRV negative [2] (Table 1). The samples were coded to blind
the analysis with regard to the putative XMRV status of the donor.
X-SCA detected high levels of MLV, but no XMRV, in all 4
samples from CFS patients (Figure 1). For reference, Figure 1a
shows the differential fluorescence seen with the amplification of
endogenous MLV (DNA extracted from mouse cells) and XMRV
Table 2. Evaluation of cell culture supernatants from virus rescue experimentsa.
DRP identifier Clinical diagnosis
Patient specimen used for
virus culture
Cells used to culture virus
(passage)b
1 CFS plasma HFF (4)
2 CFS B cells patient B cells (10)
3c lymphoma PBMC HFF (4)
4c lymphoma bone marrow HFF (2)
5 CFS plasma HFF (8)
6 CFS plasma HFF (5)
7 prostate cancer prostate tissue LNCaP (unknown)
8 CFS PBMC HFF (8)
9 CFS plasma HFF (2)
asamples obtained from LBS.
bThe indicated sources were inoculated onto LNCaP (8–12 passages) and used to infect HFF cells, which were then grown in culture for 2–10 passages, after which the
supernatants were subjected to X-SGS.
cThese samples were obtained from the same patient.
doi:10.1371/journal.pone.0030889.t002
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RNA standards. Figure 1b shows the fluorescence profiles of the
sequences amplified from the CFS patient plasma samples
compared to an XMRV RNA standard curve. These data show
that the amplification profiles from the CFS patient samples mimic
those of MLV and not XMRV. Cloning and sequencing of the X-
SCA products confirmed that the amplicons did not contain the
gag deletion specific to XMRV and preXMRV-2 sequences
(Figure 1c). We also tested the samples for XMRV or MLV
DNA by performing X-SCA without the reverse transcriptase
(RT) enzyme and found that the CFS patient samples contained
MLV DNA that was amplifiable (data not shown). These results
show that the retroviral sequences detected in the CFS plasma
samples were more similar to endogenous MLV DNA than
XMRV RNA, suggesting high levels of contamination with mouse
genomic DNA. X-SCA did not detect MLV sequences in the
samples from the healthy control patients but did detect XMRV
nucleic acid in two of the 5 samples (X4 and X7) reported to be
healthy controls by WPI. The X-SCA product was sequenced and
determined to be an exact match to XMRV (Figure 1c). Repeat
X-SCA testing of both samples gave the same results, implying
that the contamination occurred during preparation of the samples
and not during performance of the X-SCA assay. We do not know
the source of XMRV sequences in the two healthy control
samples. Both samples gave a positive PCR signal in reactions
lacking RT, but neither sample was positive for XMRV or MLV
sequences by X-SGS using an oligodT primer (Table 1). The latter
result suggests that the samples may have contained XMRV DNA
but not viral RNA molecules. These findings, taken together with
the fact that XMRV originated by recombination between two
endogenous MLVs in a xenograft of prostate cancer passaged in
nude mice, makes it likely that sample contamination with XMRV
was from cloned or PCR-amplified XMRV DNA. Additional
sample was not available to differentiate further between these two
types of DNA contamination.
Detection of mouse DNA sequences in patient plasma
samples
Because the X-SCA results suggested high levels of mouse DNA
contamination in the CFS patient samples, we used three
experimental approaches to detect mouse DNA. We tested for
mouse mitochondrial DNA using an assay that detects the COX2
gene (Table 1), for mouse genomic DNA using an assay that
Figure 1. X-SCA amplification profiles of XMRV and MLV templates. Florescence intensity as a function of cycle number is shown for X-SCA
amplifications initiated with dilutions of XMRV RNA and (a) endogenous MLVs found in mouse (TA3.Cyc-T1) genomic DNA or (b) patient plasma
samples obtained from WPI and LBS. Red lines: XMRV standards; pink: CFS patient plasma samples; green: Normal control plasma. (c) Aligned
sequences of the cloned amplicons detected in (b) from the indicated samples. The XMRV reference sequence matched vp62, virus from 22Rv1 cells,
and Pre-XMRV-2.
doi:10.1371/journal.pone.0030889.g001
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detects intracisternal A-particle (IAP) sequences [14] (Table 1),
and we performed X-SGS of a 1.4 kb fragment of the XMRV/
MLV gag gene to determine the source of the amplified nucleic acid
in plasma samples (Table 1, Figure 2). The three methods yielded
concordant results for all 9 samples and provided unequivocal
evidence that the plasma samples provided to us from 4 of the CFS
patients originally reported [12] to be XMRV infected were
contaminated with mouse DNA (Table 1). No mouse mitochondrial
or genomic DNA was detected in the 5 samples from healthy
controls by the COX2, IAP, or X-SGS assay.
To further analyze the MLV sequences obtained by X-SGS, we
prepared neighbor-joining trees from the single-genome gag
sequences obtained from the 4 CSF patient plasma samples and
from sequences obtained from strain A mouse genomic DNA
(extracted from TA3.Cyc-T1 cells). We compared these sequences
to known endogenous MLV sequences [26] (Figure 2). Plasma
samples from each of the 4 CFS patients contained MLV
sequences indistinguishable from those found in mouse genomic
DNA. Moreover, X-SGS did not detect XMRV sequences in any
of the CFS patient samples, although, as expected for mouse DNA
and described by Paprotka, et al [27], two of the sequences were
an almost perfect match to preXMRV-2 in this region (one from
X2 and one from X5). X-SGS was also performed on the env gene
from patient X8 and compared to single-genome env sequences
obtained from mouse cells (Figure 3). The majority of sequences in
patient X8 contained large deletions, as seen in the highlighter plot
of the alignment of Figure 3b (http://www.hiv.lanl.gov/content/
sequence/HIGHLIGHT/highlighter_top.html). Similarly large
env deletions were also present in the endogenous MLVs amplified
by X-SGS from mouse genomic DNA, again confirming that
mouse genomic DNA was the source of MLV sequences in the
plasma samples from the CFS patients (Figure 3b).
XMRV sequences of viruses obtained from co-cultures
with patient samples
Although contaminating mouse genomic DNA can explain false
positive results in PCR assays, it does not explain the isolation of
replicating XMRV from patients reportedly infected with XMRV
[2,28,29]. We therefore performed X-SGS analysis of superna-
tants from human foreskin fibroblasts (HFF) or LNCaP cells
infected with virus reportedly isolated from plasma, PBMCs or
tissue from 8 patients with putative XMRV infection (Table 2).
One of these patients (Patient 5; Table 2) was among the 9 patients
from whom we had evaluated viral sequences in plasma samples
(patient X5 in Table 1). As described above, plasma from patient
X5 was positive for MLV sequences but not XMRV sequences by
X-SCA, and was contaminated with mouse DNA.
X-SGS of env was performed on all 9 culture supernatants and
on gag from a subset of three supernatants (PID 1, 2, 3). XMRV,
but not MLV, sequences were detected in all 9 culture
supernatants. As shown in Figures 4 and 5 and Table 3, all of
the XMRV sequences detected in the supernatants were nearly
indistinguishable from XMRV sequences found in well-charac-
terized XMRV-infected cell lines. Specifically, Figure 4 shows the
Figure 2. Neighbor-Joining Phylogenetic Tree of sequences
obtained by X-SGS from CFS patients’ plasma samples.
Phylogenetic structure of gag single-genome sequences obtained from
CFS patients X2 (aqua) X3 (blue) X5 (green), and X8 (red), and TA3.Cyc-
T1 mouse cells (black triangles). Also includes sequences of endoge-
nous MLVs extracted from the C57Bl6 genome sequence [26], as well as
XMRV isolates are included for comparison. Where there are multiple
identical sequences in the mouse genome, only one is shown, with the
number of identical sequences in parentheses.
doi:10.1371/journal.pone.0030889.g002
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neighbor-joining tree and highlighter plot of XMRV env sequences
found in the 9 culture supernatants compared to sequences
obtained by X-SGS from 22Rv1 cells and from the 293T-XMRV
subline. Phylogenetic analysis (Figure 4, 5) and calculations of
genetic distance (Table 3) show that the viral sequences obtained
from the co-culture supernatants from 8 different patients were
nearly identical, and that these sequences are essentially the same
as those from both 22Rv1 cells and 293T-XMRV cells. XMRV
produced by 22Rv1 cells shows very low diversity (Figure 4, 5,
Table 3), whereas the XMRV sequences from 293T-XMRV cells
and co-culture supernatants were 2-16-fold more diverse (Table 3),
consistent with acquisition of a few mutations during rounds of
virus replication in cell culture that occurred during the co-culture
procedure that included 2–10 passages. Moreover, the consensus
sequences from the culture supernatants and the 293T-XMRV
cells were identical to the consensus sequence of XMRV from
22Rv1 cells (with the exception of single nucleotide changes in PID
6 and 9). Because these analyses include a region in env (shaded in
Fig. 4b) that contains multiple crossovers between PreXMRV-1
and -2 (events that occurred in the generation of XMRV and that
are highly unlikely to occur twice as explained by Paprotka, et al.
[18]), they provide very strong evidence that all of the viruses
detected here arose from 22Rv1 cells.
X-SGS of gag was also performed using supernatants of cultures
treated with samples obtained from PIDs 1–3 and 5. Although
these sequences were very similar, more detailed analyses revealed
that the culture supernatants from PIDs 1, 3, and 5 had gag
sequences that were most closely related to XMRV from 22Rv1
cells, whereas the culture supernatant from PID 2 had sequences
identical to those from 293T-XMRV cells (Figure 5).
PID 5 was the only patient for whom both plasma and virus
culture supernatant were tested. We found sequences in the
Figure 3. Env sequences obtained from plasma of patient X8. (a) Neighbor-joining analysis of full-length env sequences from patient X8, the
full length TA3 sequences, and endogenous MLV as shown in Figure 2. (b) Highlighter plot of single-genome sequence alignment of env sequences
from patient X8 and from TA3.CycT1 mouse cells.
doi:10.1371/journal.pone.0030889.g003
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plasma sample that were derived from mouse genomic DNA, and
were very different sequences detected in the co-culture superna-
tant, which were indistinguishable from the XMRV produced by
22Rv1 cells. These findings indicate that the plasma sample and
the virus co-culture from this patient were contaminated from at
least two independent sources, each of which led to different false
positive results for XMRV infection.
Discussion
Our analyses of plasma samples independently collected from
CFS patients previously reported to be XMRV-infected [2,29] and
from healthy controls reported to be XMRV-uninfected [2], and
of virus isolation co-culture supernatants identified three different
types of sample contamination, leading to false positive detection
of XMRV. First, we detected high levels of mouse genomic (both
IAP and MLVs) and mouse mitochondrial DNA, but no XMRV
sequences, in plasma samples from CFS patients, leading us to
conclude that contaminating mouse genomic DNA in this set of
plasma samples led to false positive PCR results for XMRV.
Second, although the 5 plasma samples from healthy controls were
free of mouse DNA, two of them contained contaminating XMRV
nucleic acid – most likely plasmid or a PCR amplified DNA
product – as shown by the PCR amplification profiles and
confirmed by sequencing of the amplified product. Third, our
analyses of sequences from viruses reportedly isolated from 8
patients with putative XMRV infection [29] revealed that the
sequences did not differ among the patients and were indistin-
guishable from sequences of XMRV in XMRV-infected cell lines
indicating that the cultures were cross-contaminated from infected
cell lines used in the same laboratory. Specifically, the viruses
reportedly isolated from patient samples exhibited very little
diversity and were closely related to the 22Rv1 virus, consistent
with a virus highly similar or identical to that found in the 22Rv1
cell line after a few cycles of virus replication in culture. These
findings indicate that the putative isolations of replicating XMRV
from patient samples were likely false positives as a result of cross-
contamination of the cultures with XMRV from infected cell lines.
PCR and tissue culture are sensitive methods, and are, as a
consequence, susceptible to contamination. Care must be taken both
to prevent such contamination and to ensure that the analysis includes
proper controls to exclude false positive results. The experimental
samples and controls must be collected at the same time, using the
identical materials, and processed together under identical conditions.
Furthermore, it is important to develop strict criteria for declaring a
sample positive, including a requirement that multiple methods
should yield positive and negative results for the same samples, and
the results should be reproducible. Our independent analyses of
samples from patients reported to be XMRV-infected (12), refutes
prior evidence of XMRV infection in these patients and argues
against XMRV infection of human populations.
Our data show that there are at least three different ways
contamination can be misinterpreted as XMRV or MLV infection
of humans. The first is mouse DNA, which is a ubiquitous
environmental contaminant that can find its way into experimen-
tal samples in many different ways. Examples include monoclonal
antibodies or other bioproducts prepared in mice or mouse cells,
chemicals, disposables, or other materials stored where mice can
have access [3,13,14,30,31,32], or handling of mouse specimens or
cell lines in the same laboratory where human samples are being
processed [12]. Inbred strains of mice contain around 60 MLV
proviruses per haploid genome that can be detected by PCR with
an env-specific probe [33], and some wild subspecies contain even
more. Given that approximately 50% of the proviruses may be
deleted in the env region (Fig. 3), one cell may contain over 200
proviruses that can be detected by PCR with gag, pro, or pol primers,
increasing the potential that trace amounts of mouse DNA can
give rise to a positive PCR signal. The second source of
contamination is cloned or amplified XMRV DNA, including
DNA being used as a positive control in diagnostic tests. A
microgram of XMRV DNA is approximately 1013 copies. Any
laboratory that works with either cloned or amplified XMRV
DNA is a potential source of contamination. The third source of
contamination is inadvertent spread of XMRV originating from
22Rv1 cells to indicator cells co-cultivated with clinical samples.
Although this virus is quite sensitive to human restriction factors
such as tetherin and APOBECs 3F and 3G, many established cell
lines, like 293T, do not express these factors, and cross-
contamination can occur even in laboratories with considerable
virology experience, leading to subsequent spread to other cell
lines, as was observed for the 293T-XMRV cells reported here.
Inadvertent contamination of other human cell lines provides a
plausible explanation for XMRV contamination even in labora-
tories that have never cultured the 22Rv1 cell line.
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Figure 4. Env X-SGS of culture supernatants from virus isolations. (a) Neighbor-joining tree of single-genome env sequences from XMRV
infected 293T cell supernatants, 22Rv1 cell supernatants, and supernatants from virus rescue experiments on samples 1–9. (b) Highlighter plots of the
same sequences. PreXMRV-1 and -2 and the predicted recombinant (used as outgroup) [18] are included for comparison. The region of multiple
crossovers inferred to have occurred between the two parental viruses is shaded.
doi:10.1371/journal.pone.0030889.g004
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Figure 5. Gag X-SGS on culture supernatants from isolations. (a) Neighbor-joining tree of single-genome gag sequences from XMRV infected
293T cell supernatants, 22Rv1 cell supernatants, and supernatants from virus rescue experiments on patients 1–3, and 5. (b) Highlighter plots of the
same sequences as compared to XMRV VP62. PreXMRV-1 and -2 and the predicted recombinant (used as outgroup) [18] are included for comparison.
doi:10.1371/journal.pone.0030889.g005
Table 3. Pairwise diversity of XMRV env sequences from virus culture samples.
PID % Intra-patient diversitya % Distance from 22Rv1 consensusa
1 0.05 0.03
2 0.12 0.04
3 0.16 0.09
4 0.16 0.1
5 0.05 0.02
6 0.08 0.07
7 0.02 0.01
8 0.03 0.01
9 0.16 0.11
22Rv1 supernatant 0.01 0
293T supernatant 0.13 0.07
aaverage pairwise distance calculated in Mega 5.
doi:10.1371/journal.pone.0030889.t003
Contamination in Samples Reported to be XMRV+
PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e30889
